Reply:
Domenico Sansonno, Felicia Anna Tucci, Valli De Re, Gianfranco Lauletta, Michele Montrone, Massimo Libra, Franco Dammacco – 20 April 2006
Liver disease in Egypt: Hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors
G. Thomas Strickland – 20 April 2006 – In Egypt, schistosomiasis was traditionally the most important public health problem and infection with Schistosoma mansoni the major cause of liver disease. From the 1950s until the 1980s, the Egyptian Ministry of Health (MOH) undertook large control campaigns using intravenous tartar emetic, the standard treatment for schistosomiasis, as community‐wide therapy. This commendable effort to control a major health problem unfortunately established a very large reservoir of hepatitis C virus (HCV) in the country.
Pegylated interferon–induced immune‐mediated hepatitis post–liver transplantation
Nickolas Kontorinis, Kaushik Agarwal, Nassim Elhajj, M. Isabel Fiel, Thomas D. Schiano – 20 April 2006 – A 55‐year‐old Caucasian male developed a well characterized autoimmune hepatitis after completing treatment with pegylated interferon and ribavirin for recurrent hepatitis C. We hypothesize that pegylated interferon triggered a severe form of immune‐mediated hepatitis.
Isolated right hepatic vein obstruction after piggyback liver transplantation
Federico Aucejo, Charles Winans, J. Michael Henderson, David Vogt, Bijan Eghtesad, John J. Fung, Mark Sands, Charles M. Miller – 20 April 2006 – The “piggyback” technique for liver transplantation has gained worldwide acceptance. Still, complications such as outflow obstruction have been observed, usually attributable to technical errors such as small‐caliber anastomosis of the suprahepatic vena cava, twisting, or kinking.
Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation
Norah A. Terrault, Jonathan T. Carter, Laurie Carlson, Michelle E. Roland, Peter G. Stock – 20 April 2006 – The outcome of patients with hepatitis B virus (HBV) and human immunodeficiency virus (HIV) referred for liver transplantation (LT) is unknown. A high frequency of lamivudine‐resistant (LAM‐R) HBV infection may increase the risk of liver‐related death pre‐transplantation and prophylaxis failure post‐transplantation.
Adeno‐associated virus‐mediated expression of apolipoprotein (a) kringles suppresses hepatocellular carcinoma growth in mice
Kyuhyun Lee, Sung‐Tae Yun, Young‐Gun Kim, Yeup Yoon, Eui‐Cheol Jo – 20 April 2006 – Hepatocellular carcinoma (HCC) constitutes more than 90% of all primary liver cancers. HCC is a hypervascular tumor that develops from dedifferentiation of small avascular HCC and is therefore a good target for anti‐angiogenic gene therapy.
Progress on the action plan for liver disease research
Jay H. Hoofnagle, Megan E. Miller – 20 April 2006
HCV and lipoproteins: Is oxLDL an Achilles' heel of the Trojan horse?
Marlène Dreux, Francois‐Loïc Cosset – 20 April 2006
Progressive histological damage in liver allografts following pediatric liver transplantation
Helen M. Evans, Deirdre A. Kelly, Patrick J. McKiernan, Stefan Hübscher – 20 April 2006 – The long‐term histological outcome after pediatric liver transplantation (OLT) is not yet fully understood. De novo autoimmune hepatitis, consisting of histological chronic hepatitis associated with autoantibody formation and allograft dysfunction, is increasingly recognized as an important complication of liver transplantation, particularly in the pediatric population.